vs
百利高（PRGO）与Rackspace Technology, Inc.（RXT）财务数据对比。点击上方公司名可切换其他公司
百利高的季度营收约是Rackspace Technology, Inc.的1.6倍（$1.1B vs $682.8M），Rackspace Technology, Inc.净利率更高（-4.8% vs -127.8%，领先123.0%），Rackspace Technology, Inc.同比增速更快（-0.4% vs -2.5%），百利高自由现金流更多（$148.6M vs $56.0M），过去两年百利高的营收复合增速更高（1.3% vs -0.6%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
Rackspace Technology, Inc.是总部位于美国得克萨斯州圣安东尼奥的云计算企业，在弗吉尼亚州雷斯顿以及澳大利亚、加拿大、英国、印度、迪拜、瑞士、荷兰、德国、新加坡、墨西哥、中国香港等多个国家和地区设有办事处，数据中心分布于全球多个主要城市，为客户提供专业的云计算相关服务。
PRGO vs RXT — 直观对比
营收规模更大
PRGO
是对方的1.6倍
$682.8M
营收增速更快
RXT
高出2.1%
-2.5%
净利率更高
RXT
高出123.0%
-127.8%
自由现金流更多
PRGO
多$92.6M
$56.0M
两年增速更快
PRGO
近两年复合增速
-0.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $682.8M |
| 净利润 | $-1.4B | $-32.7M |
| 毛利率 | 32.6% | 17.6% |
| 营业利润率 | -116.0% | -0.5% |
| 净利率 | -127.8% | -4.8% |
| 营收同比 | -2.5% | -0.4% |
| 净利润同比 | -3093.9% | 41.6% |
| 每股收益（稀释后） | $-10.23 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORXT
| Q4 25 | $1.1B | $682.8M | ||
| Q3 25 | $1.0B | $671.2M | ||
| Q2 25 | $1.1B | $666.3M | ||
| Q1 25 | $1.0B | $665.4M | ||
| Q4 24 | $1.1B | $685.6M | ||
| Q3 24 | $1.1B | $675.8M | ||
| Q2 24 | $1.1B | $684.9M | ||
| Q1 24 | $1.1B | $690.8M |
净利润PRGORXT
| Q4 25 | $-1.4B | $-32.7M | ||
| Q3 25 | $7.5M | $-67.1M | ||
| Q2 25 | $-8.4M | $-54.5M | ||
| Q1 25 | $-6.4M | $-71.5M | ||
| Q4 24 | $-44.4M | $-56.0M | ||
| Q3 24 | $-21.0M | $-186.6M | ||
| Q2 24 | $-108.4M | $25.0M | ||
| Q1 24 | $2.0M | $-640.6M |
毛利率PRGORXT
| Q4 25 | 32.6% | 17.6% | ||
| Q3 25 | 36.1% | 19.4% | ||
| Q2 25 | 34.4% | 19.4% | ||
| Q1 25 | 37.6% | 19.1% | ||
| Q4 24 | 33.9% | 19.2% | ||
| Q3 24 | 37.2% | 20.3% | ||
| Q2 24 | 37.0% | 19.2% | ||
| Q1 24 | 33.1% | 19.2% |
营业利润率PRGORXT
| Q4 25 | -116.0% | -0.5% | ||
| Q3 25 | 7.0% | -5.1% | ||
| Q2 25 | 4.3% | -3.8% | ||
| Q1 25 | 4.5% | -5.8% | ||
| Q4 24 | 10.0% | -4.2% | ||
| Q3 24 | 7.4% | -25.7% | ||
| Q2 24 | -2.5% | -7.9% | ||
| Q1 24 | -5.1% | -94.5% |
净利率PRGORXT
| Q4 25 | -127.8% | -4.8% | ||
| Q3 25 | 0.7% | -10.0% | ||
| Q2 25 | -0.8% | -8.2% | ||
| Q1 25 | -0.6% | -10.7% | ||
| Q4 24 | -3.9% | -8.2% | ||
| Q3 24 | -1.9% | -27.6% | ||
| Q2 24 | -10.2% | 3.7% | ||
| Q1 24 | 0.2% | -92.7% |
每股收益（稀释后）PRGORXT
| Q4 25 | $-10.23 | $-0.13 | ||
| Q3 25 | $0.05 | $-0.28 | ||
| Q2 25 | $-0.06 | $-0.23 | ||
| Q1 25 | $-0.05 | $-0.31 | ||
| Q4 24 | $-0.32 | $-0.20 | ||
| Q3 24 | $-0.15 | $-0.82 | ||
| Q2 24 | $-0.79 | $0.11 | ||
| Q1 24 | $0.01 | $-2.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $105.8M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $2.9B | $-1.2B |
| 总资产 | $8.5B | $2.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGORXT
| Q4 25 | — | $105.8M | ||
| Q3 25 | $432.1M | $99.5M | ||
| Q2 25 | $454.2M | $103.9M | ||
| Q1 25 | $409.9M | $128.0M | ||
| Q4 24 | $558.8M | $144.0M | ||
| Q3 24 | $1.5B | $157.1M | ||
| Q2 24 | $542.8M | $190.2M | ||
| Q1 24 | $658.5M | $282.6M |
总债务PRGORXT
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | $2.8B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $3.0B |
股东权益PRGORXT
| Q4 25 | $2.9B | $-1.2B | ||
| Q3 25 | $4.4B | $-1.2B | ||
| Q2 25 | $4.5B | $-1.1B | ||
| Q1 25 | $4.4B | $-1.1B | ||
| Q4 24 | $4.3B | $-1.0B | ||
| Q3 24 | $4.6B | $-949.7M | ||
| Q2 24 | $4.5B | $-756.2M | ||
| Q1 24 | $4.7B | $-787.2M |
总资产PRGORXT
| Q4 25 | $8.5B | $2.8B | ||
| Q3 25 | $10.1B | $2.8B | ||
| Q2 25 | $10.1B | $2.9B | ||
| Q1 25 | $9.8B | $3.0B | ||
| Q4 24 | $9.6B | $3.1B | ||
| Q3 24 | $11.2B | $3.1B | ||
| Q2 24 | $10.4B | $3.4B | ||
| Q1 24 | $10.6B | $3.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $59.7M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $56.0M |
| 自由现金流率自由现金流/营收 | 13.4% | 8.2% |
| 资本支出强度资本支出/营收 | 2.4% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $145.1M | $90.6M |
8季度趋势，按日历期对齐
经营现金流PRGORXT
| Q4 25 | $175.4M | $59.7M | ||
| Q3 25 | $51.7M | $70.7M | ||
| Q2 25 | $75.9M | $8.4M | ||
| Q1 25 | $-64.5M | $12.6M | ||
| Q4 24 | $312.6M | $54.3M | ||
| Q3 24 | $42.2M | $51.8M | ||
| Q2 24 | $9.5M | $24.1M | ||
| Q1 24 | $-1.4M | $-90.3M |
自由现金流PRGORXT
| Q4 25 | $148.6M | $56.0M | ||
| Q3 25 | $29.8M | $42.7M | ||
| Q2 25 | $56.7M | $-12.4M | ||
| Q1 25 | $-90.0M | $4.3M | ||
| Q4 24 | $274.9M | $34.4M | ||
| Q3 24 | $15.1M | $27.3M | ||
| Q2 24 | $-18.9M | $-14.5M | ||
| Q1 24 | $-26.5M | $-118.4M |
自由现金流率PRGORXT
| Q4 25 | 13.4% | 8.2% | ||
| Q3 25 | 2.9% | 6.4% | ||
| Q2 25 | 5.4% | -1.9% | ||
| Q1 25 | -8.6% | 0.6% | ||
| Q4 24 | 24.2% | 5.0% | ||
| Q3 24 | 1.4% | 4.0% | ||
| Q2 24 | -1.8% | -2.1% | ||
| Q1 24 | -2.4% | -17.1% |
资本支出强度PRGORXT
| Q4 25 | 2.4% | 0.5% | ||
| Q3 25 | 2.1% | 4.2% | ||
| Q2 25 | 1.8% | 3.1% | ||
| Q1 25 | 2.4% | 1.2% | ||
| Q4 24 | 3.3% | 2.9% | ||
| Q3 24 | 2.5% | 3.6% | ||
| Q2 24 | 2.7% | 5.6% | ||
| Q1 24 | 2.3% | 4.1% |
现金转化率PRGORXT
| Q4 25 | — | — | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.96× | ||
| Q1 24 | -0.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RXT
| Public Cloud Services Segment | $442.2M | 65% |
| Private Cloud Service Segment | $240.6M | 35% |
